Myeloproliferative neoplasms (MPNs) frequently come with an activating mutation in the gene encoding Janus kinase 2 (JAK2). we performed pathway-centric gain-of-function displays in JAK2V617F hematopoietic cells and discovered that the activation from the guanosine triphosphatase (GTPase) RAS or its effector pathways (mediated from the kinases AKT and ERK) makes cells insensitive to JAK inhibition. Resistant… Continue reading Myeloproliferative neoplasms (MPNs) frequently come with an activating mutation in the